Physician profile
Julia Hudson
NPI 1265937676
$2,990.29
in general payments reported to CMS, 2019-2025
13 companies · $72.07 in 2025
The $72.07 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $24.90 · 2021: $301 · 2022: $1,066 · 2023: $481 · 2024: $847 · 2025: $72.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,392 · Travel and Lodging: $8.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,392.03 |
| Travel and Lodging | $8.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,927.28 | 2021-2024 | Constellation, Total30, Dailies Total1 |
| Sight Sciences, INC. | $141.04 | 2024 | Omni Surgical System |
| Regeneron Healthcare Solutions, INC. | $138.95 | 2024-2025 | Eylea Hd |
| Astellas Pharma US INC | $132.32 | 2023-2025 | Izervay |
| Bausch & Lomb Americas INC. | $123.70 | 2022-2023 | Stellaris |
| Amgen INC. | $116.46 | 2024 | Tepezza |
| Mallinckrodt Enterprises LLC | $113.85 | 2019 | |
| Abbvie INC. | $100.19 | 2023 | |
| Allergan, INC. | $83.70 | 2019 | |
| Genentech USA, INC. | $56.56 | 2020-2025 | Vabysmo |
| New World Medical,INC. | $23.07 | 2023 | |
| Rayner Intraocular Lenses Limited | $17.32 | 2023 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Ocular Therapeutix, INC. | $15.85 | 2024 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Hudson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.